ESPE2014 Poster Category 3 Puberty and Neuroendocrinology (1) (14 abstracts)
aDepartment of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Suwon/Gyeonggi-do, Republic of Korea; bDepartment of Pediatrics, Korea Cancer Center Hospital, Seoul/Seoul, Republic of Korea
Background: GnRH agonist (GnRHa) are able to modify natural course of Central Precocious Puberty (CPP) in girls.
Objective and hypotheses: We evaluated the etiology and the effect of GnRHa in Korean CPP boys.
Method: Total 29 boys diagnosed for CPP from 2007 to 2012 were included in Ajou University Medical Center. Sellar MRI was performed in 26 of 29 patients (89.7%). CPP was diagnosed on the basis of i) onset evidence of testicular enlargement (≥4 ml) before the age of 10 years in boys, ii) bone age ≥2 S.D. above the mean value for age, and iii) pubertal LH peak after GnRH stimulation test (>5.0 UI/l).
Results: i) Mean age was 9.45±0.81 years, mean height 142.20±8.27 cm (SDS 1.42±1.20), mean bone age 12.09±1.16 years before treatment. ii) 26 boys who were evaluated for organic brain lesion were identified no abnormality in sellar MRI (0%). iii) The mean duration of treatment was 2.28±1.15 years. iv) Mean age was 11.29±0.99 years, mean height 153.53±6.60 cm (SDS 1.36±1.00), mean bone age 13.18±0.79 years after 24 months of treatment. v) There was significant increase in PAH from 172.57±9.57 cm (SDS −0.17±1.73) before treatment to 178.33±7.45 cm (0.86±1.32) after treatment of 2 years (P=0.002). vi) PAH after 24 months of treatment was associated with bone age, PAH and PAH SDS before treatment (P<0.05).
Conclusion: There was no organic brain lesion as etiology of precocious puberty in Korean boys in this study. There was an significant increase of PAH in boys who treated with GnRHa for 2 years.